Remote Post-Conditioning (RPC) in renal transplantation | Not Recruiting
Remote Post-Conditioning (RPC) in r... | Not Recruiting
Remote Post-Conditioning (RPC) in renal transplantation
RPC
Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Kidney injury after transplantation
Prof Michael Nicholson
See all trial contact details
Primary Contact Details
Not Recruiting
Recruitment Status
ISRCTN66437627
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
Background and study aims
In end-stage renal failure the usual functions of the kidney stop working. A kidney transplant is the best treatment, but it is important to find ways in which we can improve kidney function and prolong the survival of the transplanted kidney. Immediately after transplantation there is unavoidable inflammation that can reduce kidney function. This is influenced by many factors but could be reduced by using new techniques that directly target this response. The aim of this study is to find out whether a technique called remote postconditioning (RPC) can improve the function of the kidney after transplantation. Remote postconditioning (RPC) is a simple technique that activates the body’s natural defences, rather like warming up before exercising to prevent injury. We can use this to target the inflammatory response in the kidney after transplantation. The treatment involves restricting the blood flow to the leg during surgery to convey the protective effect to the transplanted kidney. We do this by inflating a blood pressure cuff placed around the lower leg in short sequenced cycles to restrict the blood flow.

Who can participate?
Patients aged 18 or over receiving a kidney transplant.

What does the study involve?
To determine whether RPC improves kidney function after transplantation participants are randomly allocated into one of the two groups. One group undergoes the RPC procedure, in which a blood pressure cuff is inflated to restrict the blood flow to the leg while the patient is under general anaesthetic during the transplant operation. For the other group the blood pressure cuff is inflated but not enough to restrict the blood flow to the leg. After transplantation participants receive the normal treatment and care associated with receiving a kidney transplant and the surgery will not be altered in any way, regardless of the group that the patient is in. In addition to normal tests to assess kidney function, various other tests will be used to measure the effects of RPC. During surgery a flow monitor is used to monitor the blood flow into the kidney immediately after transplantation. This is removed before the end of the operation and does prolong the operation in any way. Blood samples are taken to measure kidney function. Extra samples are also collected to measure the inflammatory response. Many of these are obtained at the same time as routine sampling to limit the number of times that patients are asked to give a sample. If possible, samples of urine are also collected to measure the level of kidney injury. Biopsies (samples) of the kidney are taken at various times after transplantation to determine injury and recovery and are part of normal practice. A small amount of extra tissue is taken during the biopsy for later analysis. Two extra samples will also be taken 30 minutes after transplantation and then within the first 3 days. Participants are also required to attend the normal clinic visits at weekly intervals for the first month after transplantation, then at 1, 2 and 3 months for routine patient assessment.

What are the possible benefits and risks of participating?
Participants will experience no additional effects to their lifestyles, other than that which is expected following transplantation. There are no long-term risks associated with RPC. The procedure causes a brief absence of circulation to the lower leg which can cause some discomfort but this is quickly reversed after completion. However, as the study will be performed while the patient is under general anaesthetic, no discomfort will be felt. This technique has been used in other studies with the blood pressure cuff being applied to the either the upper arm or leg and is known to cause no lasting harm or symptoms. The kidney biopsy procedure is of low risk but complications such as bleeding can occur in a small number of cases (5-8%).

Where is the study run from?
University Hospitals of Leicester NHS Trust Leicester General Hospital (UK).

When is the study starting and how long is it expected to run for?
August 2011 to August 2014.

Who is funding the study?
University Hospitals of Leicester NHS Trust and University of Leicester (UK)

Who is the main contact?
Sarah Hosgood
sah76@le.ac.uk
Research Details
  • Remote Post-Conditioning (RPC) can improve post transplant function and graft survival in renal transplant recipients
Phase
Sorry, this information is not available
Study Design
Double-blinded randomised controlled trial
Study Type
Interventional
Intervention

Patients will be randomised to either receive RPC during transplantation or the standard transplant with sham procedure

Intervention Type
Procedure/Surgery
Primary Outcome Measures
    Live donor:
    1. Slow graft function measured by creatinine fall in the first 24 hours and Area under the curve (AUC) serum creatinine over the first 7 days post transplant
    2. Graft function rates: incidences of delayed graft function and primary non-function
    3. Glomerular filtration rate (eGFR) and serum creatinine levels: 1 and 3 months
    4. Graft survival
    5. Patient survival
    6. Episodes of rejection within the first 3 months (cell and antibody mediated)

    Deceased donor:
    1. Slow graft function measured by creatinine fall in the first 24 hours and Area under the curve (AUC) serum creatinine over the first 7 days post transplant
    2. Graft function; incidences of delayed graft function and primary non-function
    3. Glomerular filtration rate (eGFR) and serum creatinine levels: 1 and 3 months
    4. Graft survival
    5. Patient survival
    6. Episodes of rejection within the first 3 months (cell and antibody mediated)
Secondary Outcome Measures
    Live and deceased donor:
    In addition, we wish to further understand the mechanisms by which remote postconditioning (RPC) conveys its protective actions.

    1. The renal blood flow into the kidney in the immediate post transplant phase will be measured using a Doppler flow probe. The renal vascular resistance will be calculated from the kidney weight and renal arterial blood flow
    2. Mediators of RPC: Nitric oxide levels and adenosine levels determined by ELISA using plasma samples taken from the renal vein 30 minutes after reperfusion and from peripheral venous samples (see blood sample protocol)
    3. Markers of ischaemic injury: Neutrophil gelatinase-associated lipocalin (NGAL)- small protein that is increased with ischaemic injury, KIM-1, Oxidative damage (protein carbonyl, Lipid peroxidation, DNA damage), Inflammation; levels of cytokines (IL-1, IL-©¬, IL-2, IL-6, IL-8, IL-10, TNF-¥á), determined using plasma and urine samples
    4. Measure the level of repair: Determination of up and down regulated genes using gene array analysis in renal biopsies. The presence of genes such as those involved in apoptosis (anti-apoptotic Bcl-2), Protection [Hemeoxygenase-1 (HO-1) and Heat shock protein (HSP)] and fibrosis will be validated by RT-PCR.
    5. Histological changes: Biopsies will be stained with H&E for histological scoring, immunohistochemistry techniques to determine injury and Sirius red (an extracellular matrix stain) to measure interstitial fibrosis
Publication(s)
Sorry, this information is not available
Result Reports
Sorry, this information is not available
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
Adult
Who Can Participate
Patient
Number of Participants
80
Participant Inclusion Criteria
    1. Age greater than or equal to 18 years
    2. Patients receiving a primary or secondary renal allograft from a live or donation after Brain Stem Death (DBD donor)
    3. Patients with second transplants must have maintained their primary graft for at least six months after transplantation (with the exception of graft failure due to technical reasons)
    4. Signed written informed consent
Participant Exclusion Criteria
    1. Blood type ABO incompatible live donor transplants
    2. Donation after cardiac death donors
    3. Patients with severe peripheral vascular disease
    4. Patients on ATP-sensitive potassium channel opening or blocking drugs
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Leicester
LE5 4PW
Trial Contact(s)
Primary Trial Contact
Prof Michael Nicholson
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
A double-blinded randomised controlled trial of Remote Post-Conditioning in renal transplantation
EudraCT Number
Sorry, this information is not available
Funder(s)
  • University Hospitals of Leicester NHS Trust (UK)
  • University of Leicester (UK)
Other Study ID Numbers
UHL 11035
Sponsor(s)
University of Leicester (UK)
Key Dates

Recruitment Start Date

21 Aug 2011

Recruitment End Date

21 Aug 2014

Trial Start Date

21 Aug 2011

Trial End Date

21 Aug 2014

Date Assigned

19 Sep 2011

Last Updated

11 Sep 2015